1. Home
  2. WHWK vs ACOG Comparison

WHWK vs ACOG Comparison

Compare WHWK & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Whitehawk Therapeutics Inc.

WHWK

Whitehawk Therapeutics Inc.

HOLD

Current Price

$3.70

Market Cap

213.2M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.63

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHWK
ACOG
Founded
2007
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.2M
193.6M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
WHWK
ACOG
Price
$3.70
$8.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$7.50
★ $16.00
AVG Volume (30 Days)
★ 242.9K
103.8K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 86.02
41.58
EPS
★ N/A
N/A
Revenue
$7,145,000.00
★ $10,220,275.00
Revenue This Year
N/A
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.86
$4.50
52 Week High
$5.50
$10.14

Technical Indicators

Market Signals
Indicator
WHWK
ACOG
Relative Strength Index (RSI) 31.90 45.06
Support Level $3.36 $8.30
Resistance Level $3.81 $9.04
Average True Range (ATR) 0.16 0.51
MACD -0.05 -0.06
Stochastic Oscillator 3.33 31.25

Price Performance

Historical Comparison
WHWK
ACOG

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: